A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Sembragiline (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MAyflOwer-RoAD
  • Sponsors Roche
  • Most Recent Events

    • 11 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 30 Jun 2015 Primary endpoint 'Change in Alzheimers Disease Assessment Scale - Cognitive Behaviour Subscale (ADAS-Cog-11) score' has not been met, according to an Evotec AG media release.
    • 14 Mar 2015 According to an Evotec media release, results from this trial are expected in the first half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top